• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23734 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Institute for Clinical and Economic Review (ICER) Ensifentrine for the treatment of chronic obstructive pulmonary disease: effectiveness and value
2024     Institute for Clinical and Economic Review (ICER) Midomafetamine-assisted psychotherapy for post-traumatic stress disorder
2024     Institute for Clinical and Economic Review (ICER) Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria
2024     Institute for Clinical and Economic Review (ICER) KarXT for schizophrenia
2024     Institute for Clinical and Economic Review (ICER) Sotatercept for pulmonary arterial hypertension
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Blood determination of a panel of anti-tuberculosis drugs using a multiplex approach by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) in the context of clinical pharmacometrics]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: clozapine blood level testing by immunoassay]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: helicobacter pylori - diagnosis, optimal treatment and follow-up]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: confirmed chlamydia trachomatis or neisseria gonorrhoeae infection]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of STAT5 phosphorylation status by flow cytometry]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of STAT3 phosphorylation status by flow cytometry]
2024     Health Information and Quality Authority (HIQA) A summary of publicly-funded services for fertility preservation for medical reasons in selected countries
2024     The Regional Health Technology Assessment Centre (HTA-centrum) Benefits and risks of emergency departments with or without a co-located primary care driven urgent care center
2024     The Regional Health Technology Assessment Centre (HTA-centrum) Umbilical cord clamping at one minute, allowing stem cell harvesting, compared with delayed cord clamping - infant and maternal outcomes
2024     Haute Autorite de sante (HAS) [Assessment of the endoscopic transluminal necrosectomy procedure in the treatment of acute necrotizing pancreatitis]
2024     Norwegian Institute of Public Health (NIPH) [Cost-effectiveness of robot assisted surgery for prostate cancer]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Stereotactic radiosurgery in benign tumors of the central nervous system]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: syndromic approach - pharmacological treatment]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: genital herpes - identification, diagnosis, optimal use of antivirals and follow-up]
2024     National Institute for Health and Care Excellence (NICE) Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome. NICE diagnostics guidance 62
2024     National Institute for Health and Care Excellence (NICE) Direct skeletal fixation of limb prostheses using an intraosseous transcutaneous implant. NICE interventional procedures guidance 795
2024     National Institute for Health and Care Excellence (NICE) MRI-guided focused ultrasound subthalamotomy for treating Parkinson's. NICE interventional procedures guidance 797
2024     National Institute for Health and Care Excellence (NICE) MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's. NICE interventional procedures guidance 796
2024     National Institute for Health and Care Excellence (NICE) Bevacizumab gamma for treating wet age-related macular degeneration. NICE technology appraisal guidance 1022
2024     National Institute for Health and Care Excellence (NICE) Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1021
2024     National Institute for Health and Care Excellence (NICE) Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal). NICE technology appraisal guidance 1024
2024     National Institute for Health and Care Excellence (NICE) Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments. NICE technology appraisal guidance 1023
2024     National Institute for Health and Care Excellence (NICE) Ublituximab for treating relapsing multiple sclerosis. NICE technology appraisal guidance 1025
2024     National Institute for Health and Care Excellence (NICE) Tirzepatide for managing overweight and obesity. NICE technology appraisal guidance 1026
2024     HTA Region Stockholm [Effectiveness and safety of intense pulsed light therapy for dry eye symptoms due to meibomian gland dysfunction]
2024     HTA Region Stockholm [Benefits and harms of intra-articular corticosteroid injections for hip osteoarthritis]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: blood cortisol and dexamethasone measurements using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) in the context of a dexamethasone suppression test]
2024     NIHR Health Technology Assessment programme Energetic activity for depression in young people aged 13–17 years: the READY feasibility RCT
2024     NIHR Health Services and Delivery Research programme A model of occupational stress to assess impact of COVID-19 on critical care and redeployed nurses: a mixed-methods study
2024     NIHR Health Services and Delivery Research programme Clinical and cost-effectiveness of first contact physiotherapy for musculoskeletal disorders in primary care: the FRONTIER, mixed method realist evaluation
2024     NIHR Health Technology Assessment programme Cervical ripening at home or in hospital during induction of labour: the CHOICE prospective cohort study, process evaluation and economic analysis
2024     NIHR Health and Social Care Delivery Program Impact of frailty in older people on health care demand: simulation modelling of population dynamics to inform service planning
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: medical imaging of the head]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: tumor biomarkers related to managing people with colorectal cancer]
2024     NIHR Health Services and Delivery Research programme Strengthening open disclosure in maternity services in the English NHS: the DISCERN realist evaluation study
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: quantification of antipsychotics in serum using high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a transcatheter tricuspid valve replacement for tricuspid valve insufficiency – addendum to project H23-03]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a transcatheter tricuspid valve replacement for tricuspid valve insufficiency – assessment according to §137h Social Code Book (SGB) V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Methods for determining the extent of added benefit - empirical data from dossier assessments]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cefepime/enmetazobactam (bacterial infections, several therapeutic indications) – Addendum to Project G24-15]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Futibatinib (cholangiocarcinoma) – addendum to Project A24-66]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bimekizumab (hidradenitis suppurativa) - Addendum to Project A24-64]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Second Addendum to Project A24-46]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [rADAMTS13 (congenital thrombotic thrombocytopenic purpura) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aztreonam/avibactam (bacterial infections, several therapeutic indications) – Assessment according to §35a (para. 1c) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sparsentan (primary immunoglobulin A nephropathy) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Maralixibat (intrahepatic cholestasis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vadadustat (symptomatic anaemia associated with dialysis-dependent chronic kidney disease) – Addendum to Project A24-67]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sotatercept (pulmonary arterial hypertension) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Epcoritamab (follicular lymphoma) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Crovalimab (paroxysmal nocturnal haemoglobinuria) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – addendum to Project A24-46]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Linzagolix (uterine fibroids) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin icodec (type 2 diabetes mellitus) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin icodec (type 1 diabetes mellitus) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (maintenance in combination with durvalumab; endometrial cancer) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (endometrial cancer) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (first-line in combination with carboplatin and paclitaxel, maintenance in combination with olaparib; endometrial cancer) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Faricimab (visual impairment due to macular oedema secondary to retinal vein occlusion) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (ulcerative colitis) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nirsevimab (secondary prophylaxis of RSV lower respiratory tract disease, 2nd. RSV season) – benefit assessment according to §35a Social Code Book (SGB) V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (solid tumours with a neurotrophic tyrosine receptor kinase [NTRK] gene fusion, > 1 month to < 12 years) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection - marstacimab (haemophilia A and B)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for onasemnogene-abeparvovec (spinal muscular atrophy): Review of the study protocol (Version 4.01) and statistical analysis plan (Version 4.0) – fourth addendum to project A20-61]
2024     Penn Medicine Center for Evidence-based Practice (CEP) Urinary catheter exchange prior to sample collection 2024 update
2024     Health Technology Wales (HTW) Non antibiotic antimicrobial anticoagulant catheter locking solutions for the prevention of catheter related complications
2024     Health Technology Wales (HTW) ELF test (Enhanced Liver Fibrosis)
2024     Health Technology Wales (HTW) Robot-assisted benign gynaecological surgery
2024     Health Technology Wales (HTW) Advanced paramedic practitioners
2024     Health Technology Wales (HTW) Digital tools for diabetes management
2024     HTA South [Intrathecal treatment of cancer pain]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: gradual return to activities following a mild traumatic brain injury or concussion (MTBI/concussion)]
2024     NIHR Health Services and Delivery Research programme Interpersonal counselling for adolescent depression delivered by youth mental health workers without core professional training: the ICALM feasibility RCT
2024     NIHR Health Technology Assessment programme Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling
2024     NIHR Health Technology Assessment programme Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis
2024     NIHR Health and Social Care Delivery Program Exploratory study from an end-of-life research partnership network to improve access for ethnically diverse communities in one region
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: pharmacokinetics, efficacy and safety of and persistence with treatment with the generic versions of Concerta compared to Concerta]
2024     WorkSafeBC Rest as treatment for adhesive capsulitis: 2024 update
2024     WorkSafeBC Causal association between sprain/strain and myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia
2024     WorkSafeBC Noise-cancelling headphones as treatment for PTSD - 2024 update
2024     WorkSafeBC Association between complex regional pain syndrome, ketamine use, lower urinary tract symptoms and erectile dysfunction
2024     WorkSafeBC Efficacy/effectiveness of nSTRIDE injection in treating patients with knee osteoarthritis
2024     WorkSafeBC Efficacy/effectiveness of axillary nerve block to treat shoulder pain
2024     WorkSafeBC Effectiveness of prolotherapy in rotator cuff tendinopathy
2024     WorkSafeBC COVID-19 and perimyocarditis
2024     WorkSafeBC Effectiveness of botulinum toxin (botox), A or B, in treating painful neuroma: 2024 update
2024     WorkSafeBC Low intensity ultrasound for treating fracture nonunion and short reviews on other bone growth stimulator devices and orthobionomics: second update January 2024
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: psychosocial interventions in youth aged under 18 with attention deficit/hyperactivity disorder (ADHD)]
2024     NIHR Health Technology Assessment programme Assessing long-term effectiveness and cost-effectiveness of statin therapy in the UK: a modelling study using individual participant data sets
2024     NIHR Health and Social Care Delivery Program Early mental health intervention and supported self-care for LGBTQ+ young people in the UK: a mixed-methods study
2024     NIHR Health Technology Assessment programme Collagenase injection versus limited fasciectomy surgery to treat Dupuytren’s contracture in adult patients in the UK: DISC, a non-inferiority RCT and economic evaluation
2024     NIHR Health Technology Assessment programme Point-of-care tests for urinary tract infections to reduce antimicrobial resistance: a systematic review and conceptual economic model
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: environmental impacts in health and social services - what role should health technology assessment agencies play?]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: care management for youth under 18 with attention deficit hyperactivity disorder (ADHD)]
2024     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [The utility of neuropsychological tests for the detection and diagnosis of frontotemporal dementia (FTD)]